Cost-Per-Responder Analysis of Bimekizumab (IL-17A/F inhibitor) against IL-17A and IL-12/23 Targeted Therapies for Psoriatic Arthritis in Spain, based on Matching-Adjusted Indirect Comparisons (MAIC)
Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons (MAIC)
Recommendations for effective patient involvement in the assessment of medical devices
La carga económica de la enfermedad meningocócica invasiva causada por Neisseria meningitidis del serogrupo B en España
Análisis coste-beneficio del diagnóstico ALK en pacientes con cáncer de pulmón no microcítico
Budget IMPACT Analysis of LESS Invasive Surfactant Administration (LISA) Technique As EARLY Rescue Strategy for Preterm Infants with Respiratory Distress Syndrome in Spain
Revisión sistemática: Impacto de las comorbilidades no-cardiovasculares sobre la calidad de vida de los pacientes con insuficiencia cardiaca crónica
Olaparib en la primera línea del carcinoma de ovario asociado a mutación BRCA: ¿es coste-efectivo en España?
Comparative Narrative Review of Oncology Value Assessment Frameworks: Enfortumab Vedotin (EV) for Treatment of Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Carga económica de la anemia asociada a la Enfermedad Renal Crónica en España
